Lexilium (Bromazepam)

Bromazepam works by binding to a specific site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This enhances the effect of the inhibitory neurotransmitter GABA, increasing chloride ion flow into neurons and producing a calming, anxiolytic effect in the central nervous system.

The appropriate dose of Lexilium is determined individually by a qualified prescriber based on the patient’s clinical condition, age, and response to therapy. Healthcare professionals adjust the regimen to achieve the desired anxiolytic effect while minimizing potential adverse reactions.

Safety data for bromazepam in pregnancy and lactation are limited. Use is generally reserved for situations where the potential benefit outweighs the possible risk to the fetus or infant. Pregnant or nursing individuals should discuss alternatives and risk assessment with their healthcare provider.

To place an order, submit an enquiry on the Lexilium product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lexilium (bromazepam) belongs to the same benzodiazepine class as diazepam, lorazepam, and alprazolam. It has a relatively intermediate potency and half‑life, offering effective anxiolysis with a lower risk of accumulation compared with longer‑acting agents. Choice among benzodiazepines depends on clinical context, duration of therapy, and patient‑specific factors.

Store Lexilium at room temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat, and direct light. Do not store in bathrooms or near kitchen appliances that generate humidity.

Lexilium is taken orally, usually with a glass of water. It can be administered with or without food, but patients should follow the prescriber’s instructions regarding timing and whether to take it with meals to avoid gastrointestinal discomfort.

The most serious risks include the development of physical dependence, withdrawal seizures upon abrupt discontinuation, severe respiratory depression (especially when combined with other CNS depressants), and rare paradoxical reactions such as increased agitation or aggression. Patients should be monitored closely for these events.

Lexilium should be avoided in individuals with known hypersensitivity to bromazepam or other benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients with a history of severe hepatic impairment unless dose‑adjusted. It is also contraindicated in those taking certain interacting medications without appropriate medical supervision.